Login

董亚琳

  • Personal Information
  • E-Mail:
  • Professional Title: 主任药师
  • Status: Employed
  • Have Any Overseas Experience: No
  • Foreign Personnel or Not: No

Papers

Current position: Home > Research > Papers

A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility

Release Time:2025-04-30
Hits:
Date:
2025-04-30
Title of Paper:
A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility
Journal:
ONCOTARGET
Summary:
Molecular epidemiological research suggests that mouse double minute 4 (MDM4) polymorphisms may be associated with cancer susceptibility, but results remain controversial. To derive a more precise evaluation, we performed a PRISMA compliant meta-analysis focused on five single nucleotide polymorphisms (rs11801299, rs1380576, rs10900598, rs1563828, and rs4245739) of MDM4. Overall, 23 studies involving 22,218 cases and 55,033 controls were analyzed. The results showed that rs4245739 was significantly associated with a decreased cancer risk in the allelic (C vs. A: odds ratio [OR] = 0.848, 95% confidence interval [CI] = 0.765-0.941, P = 0.002), heterozygous (AC vs. AA: OR = 0.831, 95% CI = 0.735-0.939, P = 0.003), and dominant (AC+CC vs. A: OR = 0.823, 95% CI = 0.727-0.932, P = 0.002) models. The association was more prominent in Asians. No significant association was found using any genetic model for the rs11801299, rs1380576, rs10900598, and rs1563828 SNPs. These results indicate that the rs4245739 polymorphism may contribute to a decreased cancer susceptibility and support the hypothesis that genetic variants in the MDM4 genes act as important modifiers of cancer risk.
Co-author:
Yajing Zhai, Yalin Dong*
Translation or Not:
No
Date of Publication:
2016-11-08